

Chronic Kidney Disease Paradigm shift from late diagnosis and treatment to earlier detection/intervention

Serge Chalhoub, DVM, Dipl. ACVIM (SAIM) BLOCK FACULTY OF CALGARY

### On the Menu

- 1. Diagnosis and prediction of feline CKD in every day practice (crystal ball?)
- 2. Pathogenesis of CKD (the great mystery)
- 3. Early diagnosis: Revenge of the biomarkers
- 4. Treatments (without getting scratched)



### Sketch

- 10 year old FS Calico
- Pre-dental exam: no concerns
  - "Getting older"
  - Weight 5.75kg (6.2kg 2y ago)
  - In-house labs:
  - USG 1.038



Feline Serum Chemistry	Result	Range
Phosphorus	1.3mmol/L	1.1-2.6 mmol/L
Calcium	2.75mmol/L	2-2.9 mmol/L
Total Protein	62g/L	54-78 g/L
Albumin	34g/L	25-39 g/L
Urea Nitrogen (BUN)	8.5mmol/L	3.6-10.7 mmol/L
Creatinine	132mol/L	44.2-180 mol/L
Sodium	152mmol/L	145-160 mmol/L
Potassium	4.2mmol/L	3.5-5.5 mmol/L
Chloride	124mmol/L	112-129 mmol/L

			-

#### Brownie

- 12 year-old DSH MN, presents for weight loss over past year, on/-off anorexia for 3 months
  - Exam: mild dehydration, dental disease, muscle loss around thighs
  - Labs: Mild NR anemia, mild hypokalemia, creatinine
     240umol/L, USG 1.024, 1+ proteinuria
     Last year: creatinine 130umol. no urine collected



### What We Traditionally Do...

#### Well 🕲

- IRIS Stage Feline CKD
- Improve quality of life
- Diagnose once a patient is symptomatic
- Diet as therapy
- Proteinuria and
   hypertension

### Still lot based t

#### Not Well 🛞

- Early diagnosis and treatment, acute kidney injury (AKI)
- We forget about post renal causes of azotemia
- Understanding the pathophysiology
   Still lots of grade 4 evidencebased treatments







Veterinary CKD Para	digm Shifts
Elliott J, et al., J Small Anim Practice, 2000 <sup>1</sup> :	
Cats with CRF fed the veterinary diet	
survived longer when compared with those	
that were not (633 died vs. 264 died).	
Ross SJ, et al., JAV	/MA, 2006 <sup>2</sup> : CKD cats fed a
renal diet survive	d longer and had fewer
uremic crises.	
Syme HM, et al., <i>JVIM</i> , 2006; King JN, et al.,	
JVIM, 2007 <sup>3</sup> : Survival of cats with CKD is	
related to severity of proteinuria and it is a	
negative prognostic indicator	
King JN, et al., JV	IM, 20074: Proteinuria
significantly decre	eased with benazepril.
Jepson RE, et al., JVIM, 2009 <sup>5</sup> : High normal	
creatinine predicted development of CKD,	
and 30% of cats aged 9+ likely to develop	
CKD.	

# 

1. Diagnosis a How do we	nd Predict do this in eve	ion of Fel	ine CKD: <sup>ce?</sup>
	СК	D?	
Decrea funct least	ise in renal ion for at <u>3 months</u>		
Renal azotemia and inappropriate USG	No azoto inapprop	emia but riate USG	No azotemia, normal USG but structural changes
75% decrease of nephron mass	6 68-70% decrea	ased renal function	Unknown





### So we have not been good at diagnosing kidney disease when...

- Creatinine is in normal range.
  There is no changes in urine specific gravity (USG).
  There are no clinical signs.
- Early CKD (IRIS Stage 1-2) has been a "mystery" – Is it real? And who cares, can't do anything about it?
- But CKD has a strong prevalence:
  - Cats 30%–40% >10 years of age
     Dogs 0.37%–3.74%<sup>8</sup>

Hence the need for advanced biomarkers







### **Predicting CKD**

Prior to advanced biomarkers

#### Take home messages:

- Hard to predict CKD
- Unclear if diet has a role
- Chronic inflammatory/ischemic diseases and CKD?
- Weight loss
- UPC and high-end creatinine



Median weight loss of -8.9% body weight in the 12 months prior to diagnosis of CKD<sup>14</sup>

Weight loss already present 3 years prior to diagnosis

 Accelerated weight loss after diagnosis, association with IRIS stage

Cos

ne co Hy A tional Mi analys Re

l (n = sis was loss wa sis had

What IRIS stage are we talking about here?





#### AC♥IM Journal of Veterinary Internal Medicine Open Access Standard Article

J Vet Intem Med 2017;31:457-464

Acute-Phase Proteins and Iron Status in Cats with Chronic Kidney Disease

R. Javard, C. Grimes, L. Bau-Gaudreault, and M. Dunn

Beckground: The role of inflummation in the development and progression of chronic kidney disease (CKD) in cats is not well characterized. Hepodin is a recently discovered acate-phase protein (APP) that plays an important role in iron metabo-lion and contributes to the development of anomain in humans with CKD.

#### and CKD progression strongly associated with worsening inflammatory mediators<sup>19</sup>

fon ing Results: Man SAA and hepickin corentrations were significantly higher and main total iron and TBC were significantly lower in the CKD group ( $P \in OS$ ). There was a guifact no positive correlation between structure creating to concernation (CRT) and 2 of the APP (SAA and hepickin  $P \in OS$ ). Itervanse in SAA and hepickin were associated with decrease in TBC and hemicative in the CKD positing a functional iron dedicescy. There was no association between structure and APP, iron status, or EPO concentrations in cases, hep-explosition in

### 2015 IRIS NAPA Meeting

AA

Cowgill et al. Is progressive chronic kidney disease a acute kidney injury? Vet Clin Small Anim 46 (2016)

-----

Functional Rids

- AKI can initiate CKD in people and dogs;
  - AKI can initiate CKD in people and dogs, why not cats?
     AKIs (such as INFLAMMATION, TOXIC OR ISCHEMIA) likely cause <u>maladaptive repair</u> <u>mechanisms</u>, which initiate CKD.
  - Changes typical of ischemic AKI are present in experimental and naturally occurring CKD; AKI can lead to CKD in cats. (Brown, et al., Vet Path, 2015)<sup>15</sup>
- Link between AKI/CKD pathologic processes?
  - Likely interconnected entities <u>Progressive</u> CKD associated to active episodic or ongoing AKI
  - <u>AKI linked to CKD</u>

Maladaptation repairs even if traditional markers return to "normal"

3. E	arly Dia	ignosis:	Biomar	kers
Biomarker	Indication	Advantages	Disadvantages	Methodology
Cystatin C	GFR, AKI	Good for CKD detection	Effect related to age and weight	Immunoassay
Retinol Binding Protein	AKI, CKD	Stable	Large variation with cats and CKD	ELISA, Western Blot
A1- microglobulin	AK Most faile	d because:	(honchton)	ELISA, immunoassay
B2-microglobulin	<ul> <li>Not rea</li> <li>Not rea</li> <li>Not in-h</li> <li>Not afformation</li> </ul>	l-time (could t nouse (not acc ordable (\$\$\$)	ake weeks) essible)	ELISA
Urinary clusterin	AKI	Early AKI, active AKI	Hemorrhage	Immunoassay
GGT	AKI	One urine sample	Unstable in acidic urine, hematuria, pyuria	Automated analyzer
NGAL	AKI, CKD	Urine, serum, plasma	Neoplasia, inflammation, hematuria, pyuria	ELISA

### Wait...Why Early Diagnosis?

#### • What's the fuss?

- Undetectable or difficult to detect changes in early kidney disease
  - Weight lossInflammation
- Ongoing damage
  Multiple mini AKI model, inflammation
- Can be tough.
- Maybe we should care...
   30% of stage 1 cats will go into stage 2 within a year

### **IRIS Stage 1**

- Has been a mystery
  - Low sensitivity in previous biomarkers (creatinine, BUN) in detection
  - Little to no research
  - No clinical signs
- Paradigm shift: we now have the ability to reliably diagnose early kidney disease (both acute and chronic)
  - <u>In-house</u> and at reference laboratory

### **SDMA**

• Symmetric dimethylarginine

- Methylated form of the amino acid arginine

- Produced by all cells and released into circulation during protein degradation
- Increases at 40% of renal dysfunction (20%-40%)<sup>20</sup>
   Isosthenuria: 67-70% function loss
- Can identify CKD an average of 10 months earlier in dogs and 17 months sooner in cats







- Increases at 75% function
- Specific
- NPV 70%
- Decreases with hyperthyroidism

**(**))

- Affected by hydration, diet (ex. meat)



- **Biologic variability 15-20%**
- Can be affected by hydration, not by diet

## What Does It Mean

- Detecting kidney disease in animals with poor BCS

   Note: new reference range for dogs <2y (<16ug/dl)</li>
- Detecting kidney diseases before azotemia or isosthenuria develops
- Monitoring of renal disease
  - Setting new guidelines for monitoring of IRIS Stage 1 patients
     Setting the stage for monitoring of treatment outcomes
     Developing earlier treatments and prevention
- Helpful with ARF/AKI
- BUT it does not tell you what disease you have (investigate, manage, monitor)
- So SDMA helps with the diagnosis and the staging of CKD





















So what stage is this cat in?



Suz	zie-Q	474	
In-House Canine Renal Chemistry	Result	Range	
Phosphorus	1.3mmol/L	1.1-2.6 mmol/L	
Calcium	2.75mmol/L	2-2.9 mmol/L	
Urea Nitrogen (BUN)	8.0mmol/L	3.6-10.7 mmol/L	
Creatinine	126mol/L	44.2-180 mol/L	
Sodium	152mmol/L	145-160 mmol/L	
Potassium	4.2mmol/L	3.5-5.5 mmol/L	
Chloride	124mmol/L	112-129 mmol/L	

_				

Suz	ie-Q	-
In-House Canine Renal Chemistry	Result	Range
Phosphorus	1.3mmol/L	1.1-2.6 mmol/L
Calcium	2.75mmol/L	2-2.9 mmol/L
Urea Nitrogen (BUN)	8.0mmol/L	3.6-10.7 mmol/L
• Evidence of AKI; Suzi	e-Q is in	trouble
Real-time analysis ca	in change	e our appro
<ul> <li>Utility for monitoring</li> </ul>	g	
Chloride	124mmol/L	112-129 mmol/L
SDMA	17 µg/di	<14 µg/dl





PLOS	
	RESEARCH ARTICLE
	Serum concentrations of symmetric
	dimethylarginine and creatinine in cats with
	kidney stones
	Jean A. Hail <sup>1</sup> *, Maha Yerramilli <sup>2</sup> , Edward Obare <sup>2</sup> , Jun Li <sup>2</sup> , Murthy Yerramilli <sup>2</sup> , Dennis E. Jewell <sup>3</sup>
	1 Department of Biomedical Sciences, College of Veterinary Medicine, Oregon State University, Corvallis, Oregon, United States of America, 2 IDEXX Laboratories, Inc., One DEXX Drive, Westbrock, Mana, United States of America. 3 Per Martino Concerner Hills PR Hartition, Inc. Tooses, Kansas, Leidel States of America.
43 cats wit	th kidney stones vs. 21 healthy geriatric cats <sup>23</sup>
• 39/43 h	ad increased SDMA (92% vs. 17% azotemic)
• Only	y 18/43 had elevated creatinine at some point
(429	6)
• USG	; i > 1.035 in 15/39******
• 27 r	nonths before creatinine increased in these cases

### CKD Prognosis<sup>24</sup>

#### Cats

- Depends on how fast disease progresses

   Can have stable disease for years
- IRIS Upper Stage 2: median survival time 1151 days
  - IF not proteinuric or hypertensive (both negative prognostic indicators)
  - IF treated appropriately
- IRIS Stage 3: 679 days
- IRIS Stage 4: 35 days

#### Dogs

- CKD cats usually live longer than CKD dogs
  - Proteinuric diseases more common in dogs and have worse prognosis
     Actorial hypertension
- Stage 3 + 4
  - Usually more progressiveMonths to years to death
  - Proteinuria and hypertensic

### 

### 4. Treatments

Goals

Improve quality of lifeMinimize uremic syndrome

Prolong life

- Slow progression of disease
   As disease progresses, more
- Prevent the disease?
- Owner's quality of life





### As you will see, all current treatments are for IRIS 2 and above

- Why???
  - Poor ability to diagnose earlier
  - No clinical signs so why treat?
  - Minimal research up to this point



• So what's the point of early diagnosis?



### **Renal Diet**

#### Cats

- 2006 Ross et al: Randomized study (24 months)<sup>2</sup>
- Cats in mid-stage 2 or 3
- Uremic crisis 0% vs. 26<sup>9</sup>
- Death from renal cause 0% vs. 22%
- <u>No change in LBM</u>

#### Clinical evaluation of dietary modification for treatment of spontaneous chronic kidney disease in cats

Sheri J. Ross, twor, riso, nacvos; Carl A. Osborne, twor, riso, nacvos; Claudia A. Kirk, twor, riso, nacvos; Stephen R. Lowry, riso; Lori A. Koehler; David J. Polzin, trova, riso, nacvos;

Elliott et al 2000: Cats lived 2.5y longer at IRIS stage 3 on RD<sup>1</sup> Plantinga et al 2005: RD survival 16 months vs. 7 months<sup>27</sup>

### **Renal Diet**

• Nausea

• Appetite

Hydration

Initially diagnosed CKD cats need to be treated as <u>GI</u> <u>patients first</u>

### What If We Could Treat Prior to Clinical Signs (Stage 1)?

Jepson 2009: 30% cats in IRIS Stage 1 will progress within 1 year<sup>5</sup>

80 cats aged over 9 years age, all had normal creatinine at start<sup>28</sup>
- Renoprotective test food vs. owner-choice food

Over 6 months: SDMA did not change for cats fed renal diet vs. increase in SDMA in owner-fed diet

In renal diet: BUN and creatinine dropped

- 30% started at or developed stage 1 CKD based on SDMA - SDMA increased in most cats on owner-fed diet
- SDMA decreased or stayed stable on renal diet

#### Journal of Animal Physiology and Animal Nutrition

Hall JA, Fritsch DA, Yerramilli M, Obare E, Yerramilli M, Jewell DE. A longitudinal study on the acceptance and effects of a therapeutic renal food in pet dogs with IRIS-Stage 1 chronic kidney disease. J Anim Physiol Anim

lutr. http://onlinelibrary.wiley.com/doi/10.1111/jpn.12692/full. Accessed September 19, 2017.<sup>29</sup>

- Current IRIS guidelines: feed renal diet at stage 2+
- Unknown if earlier benefit or if detrimental:
  - Prospective 12 month trial of 36 dogs IRIS Stage 1 fed renal diet (44 clinical sites):
    - 97% of dogs transitioned successfully, majority enjoyed the new diet
    - BUN, creatinine, SDMA significantly decreased from baseline at 3 months
    - 12/16 dogs with proteinuria had significant decrease
    - Owners: overall health and quality of life attributes, hair

coat

### **The Diet Controversy**

#### The Pro and Con View of Renal Diets at Stage 2-432,33

	The Pr	o view	
Renal di	ets improv	ve survival,	

- decrease uremic crises Not just about the protein: phosphorus, sodium, omega-3, antioxidants, potassium, vitamin D, neutral effect on pH
- Protein restriction decreases uremia Phosphorus unlikely controlled with binders
- Phosphorus linked to CKD progression
- High protein leads to proteinuria and glomerular lesions
- Uremia causes weight loss,
- sarcopenia
- High protein diets untested and likely dangerous recommendation
- Promote eating

- The Con View Obligatory carnivores that need high protein diets, lose LBM with lower protein diets
- Remnant kidney studies showed no association between high protein intake and renal lesions, proteinuria, or decreased GFR
- No study has looked just at protein CKD diet effect on proteinuria unclear (Ross 2006)
- Increased mortality with lower BW CKD
- Phosphorus restriction alone not studied
- Fatty acids? What about acid-base status correction Geriatric cats may need more than 32-34% of calories from protein

#### The New Paradigm: Early diagnosis and intervention has benefits:

- May slow CKD progression
- Early diagnosis = earlier intervention for proteinuria and hypertension
- Stage 1: either a "renal friendly" diet: lower phosphorus and sodium, higher omega-3 fatty acids, not acidifying, anti-oxidants (geriatric diet), or an early-stage renal diet

### Paradigm shift in our thinking

### **Appetite Stimulants**

© 2013 Else Ted. All ri

The Veterinary Journal E.CL enane: www.elsevier.co Mirtazapine as an appetite stimulant and anti-emetic in cats with chronic kidney disease: A masked placebo-controlled crossover clinical trial J.M. Quimby \*\*, K.F. Lunn b ment of Clinical Sciences, Cuiloge of Veterinary Medicine and Biomedical Sciences, Colorado State University, 300 West Deale Road, Fort Cellin ment of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, 1060 William Moore Drive, Radeigh, NC 27607, USA Significant increase in appetite, anti-nausea properties, evaluate the effects of with stable CKD were y for 3 weeks. After a activity, and weight; decrease in vomiting<sup>34</sup> Internet period and ome-tere the reaction of the statistically significant decrease in wanting (P=0007), and determined by Witching (P=0007) and a statistically significant decrease in wanting (P=0007), and bodyweight compared with placeho-teneod case (P=0007) as determined by Witching and and significant decrease in the statistical statistical statistical and and and angle that sharing placeho administration was 007 at (pand) of 0.04 kg, Mitstagning in an effective appeties stimulum and anti-mentic for case with ODD and could be a worth adjunct to the startistical management of there cases.

### **Appetite Stimulants**

Transdermal mirtazapine in healthy source and clinical effect of source and clinical effect of s	1.0 0 The Autorup) 2016. Reports and permissions support ou university remains new IOL 10 1177/008012010007108 plm.com This paper was handled and processed by the American Gabrial Ofice (AAP) for publication on JTMD	
Min Kellyi K Benson, Lara B Zajic, Paula K Morgan, Sarah R Br witt Daniel J Hansen, Paul J Lunghoter, Luke A Wittenburg, witt Daniel L Gustafson and Jessica M Guimby Clini	SAGE own,	
Abstract Creation Creatio	n <b>gel compounds<sup>3</sup></b> tite n equency administratio	sight benefit a properties. the effects of e COD were reks. After a cal examina-
concentrators even insecuted angle liquid contratographylaride must spo Results Press L administration of IWL activated measures list services carving, and resultation of the assist synthesist Phylaride and the the Phylaride IC and the answer of the administration Phylaride angle and the phylaride angle and the administration of the administration of the angle angle synthesis in containing and the administration of the administration of the administra- short and the administration of the administration of the administration of the administration angle do ministration data with angle does. Conclusion and relationers INC 7.5 mg data y activate measurable server one seponds presented on the administration of the administration of the administration of the administration data with angle does.	connectionable, and a series designed and get connectionable, and an anne (MAC) (P = 0.02) ato (P = 0.00), rate of floor ingestion (22) at home. In hospital there was a usite (P < 0.05), dial concernitations contrations and produces significant side effects denote a lower dose is	recrease in appe- g (P+0.047) as aned significant ared model and- 145 kg). Median e is an effective > the nutritional rights reserved.

## **Ghrelin Receptor Agonists**

### Hormone mainly produced by stomach

- Hormone mainly produced by stomac "Hunger hormone" Homeostasis and energy metabolism Distribution and rate of energy usage Increased GH, IGF-1 Increased GH, IGF-1 Increase in lean muscle mass Negative feedback on its own secretion Anti-inflammatory properties

#### • Ghrelin agonists

- Capromorelin
   Eageles increase in weight and appetite
   200 dogs field study: significantly increased appetite and weight 70%<sup>36</sup>
   40 cats CKD pilot field study over 90 days: significant increase in weight vs.
   placebo<sup>33</sup>

Chronic use of ma the management o and inappetence is chronic kidney dis placebo-controlled	ropitant for of vomiting n cats with ease: a blinded, I clinical trial	orti, via trate con dari o (di March Adri 2014 lisposta and pomolaritation todo 14 (1777/2008 (disk 646.644.4) pits cont SAGE
lessica M Quimby <sup>1</sup> , William David Bolotin <sup>3</sup> and Kayla Po	T Brock <sup>1</sup> , Kelsey Moses <sup>2</sup> , atricelli <sup>2</sup>	
Abstract Dejectives Manopitant is commonly u that longer form usage appears safe. of chronic vomiting and inappetence Mithods Forty-one cats with stat concurrent illness, and a comptain in a reinformated, caleaded users	sed for acute voniting. A pharmacokin The aim of this study was to assess the associated with feline chronic kidney as International Renal Interest. Soc et of chronic vomiting and inappete	hetic and toxicity study in cats indicated efficacy of manopitant for management disease (CKD). alory Stage II or III CKD, no known nce attributed to CKD were enrolled
in a randomized, placebo-col utnalyeis, urine culture, T4 a dose of 4 mg orally (median vomiting incidence, appatite serum biochemistry were perf compare treatment groups.	Significant vomiting ov	decrease in ver 2 weeks <sup>38</sup>
Ill cats) and 12 cats received placeb diobrases in vomiting in cats with Ch have statistically significant different with placebo.	o (seven Stage II cats, five Stage III c D that received manoptant (P <0.01) ses in appetite scores, activity scores et was demonstrated to palliate vemi	ats). There was a statistically significant Calls that received marcelatant did not weight or serum creatinine compared ting associated with CKD, and may be



of 4 mg transformal ordinatetron. Conclusions and relevance Transformal application of 4 mg ondaneetron does not result in clinically relevant serum concentrations of drug. Despite characteristics of the drug that mg/s utilability for transformal application, this does not appear to be an acceptable method of drug delevery for this modicion at this does. This study

### Stem Cells

SAGE

Assessment of intravenous adiposederived allogeneic mesenchymal stem cells for the treatment of feline chronic kidney disease: a randomized, placebo-controlled clinical trial in eight cats

Jessica M Quimby<sup>1</sup>, Tracy L Webb<sup>1</sup>, Elissa Randall<sup>2</sup>, Angela Maroll<sup>9</sup>, Alex Vaides-Martinez<sup>3</sup> and Steve W Dow<sup>1,3</sup>

# No significant improvement in renal function when given IV<sup>41</sup>

In the expedied. CRC call were control in a rendomized pacebo correlated, binded now we consover clinear lands in pacebo control in the experimental system of the experimental pacebo correlated, binded now we can be experimented and pacebo control in the experimental system of the experimental pacebo control in the experimental and the comparison of the experimental system of the experimental pacebo control in the experimental and the comparison of the experimental system of the experimental pacebo control in the experimental experimental system of the experimental system of the experimental system of the experimental experimental system of the experimental system of the experimental system of the experimental experimental system of the experimental system of the experimental system of the experimental experimental system of the experimental system of the experimental system of the experimental experimental system of the experimental system of the experimental system of the experimental experimental system of the experimental system of the experimental system of the experimental experimental system of the experimental system of the experimental system of the experimental experimental system of the experimental system of the experimental system of the experimental experimental system of the experimental system of the experimental system of the experimental experimental system of the experimental system of the experimental system of the experimental system of the experimental experimental system of the expe

Sando Social received free datas el altogener teno conservativamente provincia de la conservativa tenore altora, los espectarios en la conservación de la conservación de la conservación de la conservación sucase antimismos en la conservación de la conservación de la conservación de la conservación de conservación de la conservación de la conservación de la conservación de la conservación de conservación de la conservación de la conservación de la conservación de sucase antimismos de la conservación de las conservaciones de las conservaciones nanacionada de la abevaria altera a conservación de las conservaciones de las conservaciones enterestantes. Los portes holeses de nanaciones y la delarma entere de las conservaciones deces antes antes de las desentantes. Los portes holeses de nanaciones y la delarma entere de las conservaciones delas de las delas de las delas delas delas delas delas delas delas delas delas de las delas de las delas de las delas de las delas de las delas delas de las delas delas

### Secondary Renal Hyperparathyroidism

#### PHOSPHORUS CONTROL IS A REAL PROBLEM

Secondary renal hyperparathyroidism common in CKD 76-84% dogs/cats, certainly in stage 4

- Geddes 2013 JVIM<sup>42</sup>: FGF-23 increases in cats with CKD and correlated with staging
- If phosphorus control is so important, why would we feed a high protein diet? Finch 2012 JAVMA<sup>43</sup>: PTH higher in nonazotemic cats that developed azotemic CKD within 12 months and this prior to any changes in phosphorus
- Finch 2013<sup>44</sup>: FGF23 predicted development of azotemic CKD over 12 months

Geddes 2015 JVIM<sup>45</sup>: FGF-23 associated with survival in azotemic CKD



Evaluating Sucralfate as a Phosphate Binder in Normal Cats and Cats with Chronic Kidney Disease

lessica Quimby, DVM, PhD, DACVIM, Michael Lappin, DVM, PhD, DACVIM

- Normal cats vomit with sucralfate
- CKD cats vomit even more with sucralfate
- No changes in phosphorus (study stopped)<sup>47</sup>
   vomiting occurred after 14.7% of administrations. Of the five normophosphatemic cats with CKD treated with sucratate

Tomma pocurity and the two automatications of the intervention polyateration can and evention initiation and automatic three experienced efficient decomposition, including vomiting, anoresia, constitution and unrave accention. Administration of sucraftate did not result in significant changes in focal phosphorus concentration in these cats. The effects of sucraftate administration on serum phosphorus concentration and unravy excretion of phosphorus in CKD cats was difficult to determine because of dehydration and worsening azotemia associated with decompensation. Due to side effects and the apparent tack of efficacy of the medication, the study was discontinued. This study was unable to confirm efficacy of this sucraftate formulation as a phosphate binder, and side effects were problematic during the study. (J Am Am Hosp Assoc 2016; 52:6-12. DOI 10.5350/JAV44-M-8213)

### **Uremic Gastropathy**

J Vet Intern Med 2014;28:827-837

Relationship among Serum Creatinine, Serum Gastrin, Calciumphosphorus Product, and Uremic Gastropathy in Cats with Chronic Kidney Disease

S.M. McLeland, K.F. Lunn, C.G. Duncan, K.R. Refsal, and J.M. Quimby

ad: Chronic kidney disease (CKD) in cats is associated with eastrointestinal siens

GI ulceration not found in any stage of CKD<sup>48</sup>

But evidence of gastric mineralization especially in moderate/severe azotemia

Ca X P product associated with disease severity and mineralization

### Anemia of Renal Disease

etc. and there is a disk or require grant when drawn increases are not a set of a set of the set

te Use of Darboportin to Stimulate Erythropolasis in Chronic Ridney Disease in Cats: 25 Cases

- Cats: renal anemia 30-65% of CKD patients
- <u>Anemia independent predictor of progressive</u> <u>CKD, increased mortality</u>
- Tx: Epogen, Darbepoetin

   Darbe has MUCH lower pure red cell aplasia<sup>50</sup>
   <10% vs. 25-40% Epogen</li>

### When to Treat Renal Proteinuria?

- IRIS currently recommends UPC >0.4 once azotemic
  - Syme 2006<sup>3</sup>: survival 1000d with UPC<0.2, 500d with UPC 0.2-0.4, 400d with UPC > 0.4
  - Chakrabarti 2012<sup>25</sup>: UPC was 0.23 in progressive cases and 0.13 in stable cases
  - Jepson 2009<sup>5</sup>: Group that developed azotemia had proteinuria at entry but in low levels (<u>UPC 0.14 vs. 0.19</u>)

Paradigm shift in our thinking







## **My CKD Monitoring**

	Stage I-II	Stage III	Stage IV
Test	Frequency	Frequency	Frequency
Physical	q 6 months	q 3-6 months	Monthly
Biochemistry/SDMA	q 6 months	q 3-6 months	monthly
CBC	q 6 months	q 3-6 months	q 1-2 months
Urinalysis/UPC	q 6 months	q 6 months	q 3 months
Culture	q 12 months	q 12 months	q 3 months
BP	q 6 months	q 3-6 months	q 3 months
Ultrasound	As needed	As needed	As needed

## My Geriatric Cat Monitoring (age 8+)

Test	Frequency
Physical	q 12 months
Weight	q 6 months
Biochemistry/SDMA	q 12 months
СВС	q 12 months
Urinalysis/UPC	q 12 months
BP	q 12 months
How would have Sketch's Ruled out post renal ca Early renal diet Closer monitoring of U More care with anesth	care changed? auses IPC, BP esia, medications



IRIS Stage 1? Monitor, early stage diet, BP, UPC, phosphorus		CKD? - SDMA - Renal azotemia - 3months		
IRIS Stage 2 and above?	Hydration Status?	Appetite?	IRIS Substage?	Anemia?
Renal diet recommended	Subcutaneous fluids if needed	If poor, rule out nausea, other disease	Diagnose/mon itor/treat proteinuria, hypertension	If NR and below threshold, with decrease in quality of life, consider tx
High phosphorus? Recheck once start diet; if yes then tx	Re-evaluate hydration needs	Appetite stimulants, anti- nausea medications, antacids	Rule out/monitor for UTIs	Blood transfusion, ESA, iron dextran

### Conclusion

- CKD is a progressive, serious disease
- Lots that we know, even more we don't know
- Early diagnosis important
- New treatments aimed at slowing disease down
- Change in paradigm from diagnosis/treatment when clinical signs are present, to earlier diagnosis/treatment and maybe prevention

schalhou@ucalgary.ca